Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A surge in implied volatility on a specific HCA options contract drew attention this week, alongside mixed analyst estimate changes for the hospital operator.
THE APEX TIMES
THE APEX TIMES
JNJ closed at $228.17 on June 4, 2026, up 2.21% as a recent market wrap characterized the move as outperforming the broader market. The next major company update is scheduled for mid-July.
THE APEX TIMES
After its Covid-era vaccine surge, Moderna is again positioning its platform for future outbreaks, with a market report highlighting progress in Ebola vaccine development.
THE APEX TIMES
The insurer’s quarterly cash dividend rises from $2.21 to $2.32, payable June 23 to shareholders of record June 15, continuing a long-running payout schedule.
THE APEX TIMES
Moderna’s stock rose in the afternoon after the company and Merck presented long-term results for intismeran autogene, a personalized mRNA-based cancer vaccine, in high-risk melanoma.
THE APEX TIMES
UNH rose sharply in the afternoon session as Bank of America upgraded the insurer to “Buy” and UnitedHealth authorized an increased cash dividend payable in June.
THE APEX TIMES
A roundup of recent dividend declarations highlighted UnitedHealth, Donaldson, Lowe’s, ePlus and Toronto-Dominion Bank, reflecting investor demand for income streams during a volatile macro backdrop.
THE APEX TIMES
The deal gives Pfizer early access to Chai-3 and a custom version of the platform built with Pfizer’s proprietary data, as the two companies move from AI research toward deployment inside drug discovery workflows.
THE APEX TIMES
CVS Health said its pharmacy benefit manager will restore coverage of Eli Lilly’s weight-loss injection Zepbound on Oct. 1, and begin covering Lilly’s new oral GLP-1 therapy Foundayo on June 1, reversing a prior coverage restriction.
